Early effectiveness of the BNT162b2 LP.8.1 vaccine against COVID-19 emergency department, urgent care, and outpatient visits in the US Veterans Affairs Healthcare System
Appaneal, H. J.; Lopes, V. V.; Nguyen, J. L.; Volkman, H. R.; Zasowski, E. J.; Caffrey, A. R.
Show abstract
This study estimated early vaccine effectiveness (VE) of the BNT162b2 LP.8.1-adapted vaccine against emergency department/urgent care (ED/UC) and outpatient visits using a test-negative case-control design. Patients from the US Veterans Affairs Healthcare System with an acute respiratory infection (ARI) who underwent SARS-CoV-2 testing from September 10 - November 30, 2025 were included. VE was estimated using multivariable logistic regression adjusted for patient demographics and clinical characteristics. Among 34,455 ARI episodes, 10.7% were COVID-19 cases and 2.4% were vaccinated. BNT162b2 LP.8.1 vaccine was effective during the early 2025-2026 respiratory virus season. VE was 57% (95% confidence interval [CI] 39%-70%) against ED/UC visits and 54% (95% CI 15%-75%) against outpatient visits at approximately 4 weeks post-vaccination. These findings inform shared decision-making in clinical practice and support the continued importance of COVID-19 vaccination in populations for whom it is recommended.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- 2024-2025 BNT162b2 COVID-19 vaccine effectiveness in non-immunocompromised adults: mid-season estimates from vaccine registries in two states linked to administrative claims 97%
- Safety Monitoring of Health Outcomes following Influenza Vaccination during the 2023-2024 Season among U.S. Medicare Beneficiaries Aged 65 Years and Older 96%
- Relative effectiveness of booster vs. 2-dose mRNA Covid-19 vaccination in the Veterans Health Administration: Self-controlled risk interval analysis 95%
Similar papers in this journal
- Effectiveness of the 2023-2024 Omicron XBB.1.5-containing mRNA COVID-19 vaccine (mRNA-1273.815) in preventing COVID-19-related hospitalizations and medical encounters among adults in the United States: An interim analysis 96%
- Effectiveness of BNT162b2 XBB Vaccine against XBB and JN.1 Sub-lineages 95%
- Effectiveness of the Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine 93%
Similar papers in this journal
- Viral dynamics of Omicron and Delta SARS-CoV-2 variants with implications for timing of release from isolation: a longitudinal cohort study 93%
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 93%
- Post-vaccination SARS-CoV-2 infections and incidence of the B.1.427/B.1.429 variant among healthcare personnel at a northern California academic medical center 93%
Similar papers in this journal
- Anti-nucleocapsid antibodies following SARS-CoV-2 infection in the blinded phase of the mRNA-1273 Covid-19 vaccine efficacy clinical trial 94%
- Effectiveness of mRNA COVID-19 vaccine boosters against infection, hospitalization and death: a target trial emulation in the omicron (B.1.1.529) variant era 93%
- Clinical Trends Among U.S. Adults Hospitalized with COVID-19, March-December 2020 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.